191
Views
18
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies

, , , , , , , , & show all
Pages 483-489 | Received 30 Jun 2015, Accepted 06 Aug 2015, Published online: 04 Nov 2015
 

Abstract

This study explores the imaging and therapeutic properties of a novel radiopharmaceutical, 131I-CLR1404. Phase 1a data demonstrated safety and tumor localization by SPECT-CT. This 1b study assessed safety, imaging characteristics, and possible antineoplastic properties and provided further proof-of- concept of phospholipid ether analogues’ retention within tumors. A total of 10 patients received 131I-CLR1404 in an adaptive dose-escalation design. Imaging characteristics were consistent with prior studies, showing tumor uptake in primary tumors and metastases. At doses of 31.25 mCi/m2 and greater, DLTs were thrombocytopenia and neutropenia. Disease- specific studies are underway to identify cancers most likely to benefit from 131I-CLR1404 monotherapy.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.